Legend Biotech Corp. · NASDAQ:LEGN
Legend Biotech — Q1 2024 Earnings Presentation
17 slides from Legend Biotech's earnings presentation, May 13, 2024
Slide 1: First Quarter 2024 Financial Results & Corporate Update
May 13, 2024 First Quarter 2024 Financial Results & Corporate Update This presentation is for investor relations purposes only - Not for product promotional purposes 1
Slide 2: Forward-looking Statements
Forward-looking Statements This presentation has been prepared by Legend Biotech Corporation (“Legend Biotech” or the the licensing transaction; Legend Biotech’s expectations on advancing their pipeline and “Company”) solely for information purpose and does not contain all relevant information produ
Slide 3: Agenda
1 Opening Remarks 2 Q1 2024 Performance Overview Agenda 3 4 Our Pipeline Financial Performance 5 Upcoming Milestones 6 Q&A 3 This presentation is for investor relations purposes only - Not for product promotional purposes
Slide 4: Opening Remarks: Ying Huang and Lori Macomber
Forward-looking Statements Ying Huang, PhD Lori Macomber Chief Executive Officer Chief Financial Officer 4 This presentation is for investor relations purposes only - Not for product promotional purposes
Slide 5: Business Highlights
Business Highlights C O N T I N U E D P R O G R E S S A G A I N S T O U R S T R AT E G I C P R I O R I T I E S Establishing a strong Strengthening our Unlocking value across Maintaining a solid financial foundation for CARVYKTI® manufacturing capabilities our broader pipeline position to fund sustai
Slide 6: CARVYKTI® Regulatory Approval Progress
CARVYKTI® Regulatory Approval Progress Approved for patients with RRMM in: ▪ U.S. (2L+)* – first and only BCMA-targeted therapy approved by FDA for treatment of 2L+ MM ▪ E.U. (2L+)* ▪ Brazil (2L+)* ▪ Japan (4L+) Supported by extensive, long-term clinical data available across multiple lines of t
Slide 7: Unlocking the Blockbuster Global Market Opportunity
Unlocking the Blockbuster Global Market Opportunity MULTIPLE MYELOMA PATIENTS ELIGIBLE FOR Europe CAR-T THERAPY EC approval for 2L+ MM North America FDA approval for 2L+ MM • Frontline: ~52k patients APAC MHLW1 approval for 4L+ MM • 2L to 4L: ~80k patients • 5L+: ~22k patients South America ANVISA2
Slide 8: Unleashing the Strength of CARVYKTI®
Unleashing the Strength of CARVYKTI® is a potential Best-in-Class CAR T approved in MM • Entered into a Master Manufacturing and Supply Services Agreement with Novartis1 to supplement existing manufacturing capabilities, increase commercial supply, and On track to reach 10,000 meet global demand of
Slide 9: US and EU CARVYKTI® Supply Overview
US and EU CARVYKTI® Supply Overview GLOBAL CAPACITY GLOBAL CAPACITY RAMP UP ROADMAP Facilities → Increase Current Expansion/Process Optimization Raritan Output Tech Lane → Add Supply Online Facilities Driving To Full Capacity Nodes → Ramp Plants to Full Capacity Obelisc Online Raritan Physical Rarit
Slide 10: CARVYKTI® Uptake Continues
CARVYKTI® Uptake Continues Continued market penetration, population in earlier lines of treatment represents significant opportunity for continued growth CARVYKTI® Net Trade Sales ($MM) YoY Growth QoQ Growth U.S. 100% -4% +118% growth vs Q1’23 180 EU 700% 23% 160 13 Global 118% -1% 12 16 140 140 120
Slide 11: A New Standard for CAR-T Launches
A New Standard for CAR-T Launches CARVYKTI® - INDUSTRY FIRST EIGHT QUARTERS L E A D I N G E A R LY L A U N C H OUTPERFORMING HISTORICAL PERFORMANCE CAR-T LAUNCHES WORLDWIDE SALES OF CAR -T THERAPIES, BY QUARTER OF LAUNCH (IN $MM) 400 380 Kymriah Yescarta Tecartus Breyanzi Abecma Carvykti 350 300 Qua
Slide 12: Our Pipeline
Our Pipeline Cilta-cel Clinical Studies PHASE 1 PHASE 2 PHASE 3 CARTITUDE-5* CARTITUDE-6* BCMA-directed LEGEND-2† CARTIFAN-1* CARTITUDE-1* CARTITUDE-2* CARTITUDE-4* NDMM NDMM RRMM autologous RRMM RRMM RRMM MM 1-3 Prior Lines Transplant Not Transplant NCT03090659 NCT03758417 NCT03548207 NCT04133636 I
Slide 13: Q1 2024 Financial Highlights
Q1 2024 Financial Highlights Total Revenue (in $MM) Net Loss (in $MM) EPS (in $) KEY TAKEAWAYS 100 0 0.00 Total revenues increased by 159% -53% compared 1Q23. 90 -0.05 -20 -0.16 • Collaboration revenue 80 +159% -0.10 -60 increased 116% driven by 70 -0.15 -40 -0.34 increased sales of CARVYKTI® -47% 6
Slide 14: Focused Investments in Commercialization and Pipeline
Focused Investments in Commercialization and Pipeline • 1Q 2024 OpEx increased 26% versus 1Q 2023 o Research and development spend increased by $16.1 million for continuous R&D activities in cilta-cel, including start up costs for clinical production in Belgium and continued investment in solid tumo
Slide 15: Upcoming Milestones
Upcoming Milestones Receive positive ODAC recommendation supporting potential CARVYKTI® label expansion. Obtain FDA approval for CARVYKTI® in relapsed and lenalidomide-refractory 1-3 prior lines MM indication based on CARTITUDE-4. Regulatory Receive positive CHMP recommendation supporting potential
Slide 16: Q&A
Q&A Ying Huang, Ph.D. Lori Macomber Chief Executive Officer Chief Financial Officer Guowei Fang, Ph.D. Steve Gavel Chief Scientific Officer & Head of SVP of Commercial Development, Business Development US and Europe 16 This presentation is for investor relations purposes only - Not for product promo
Slide 17: Thank you!
Thank you! 17 This presentation is for investor relations purposes only - Not for product promotional purposes